Inventor · disambiguated record
Nicolas Stransky
Also filed as: STRANSKY NICOLAS
10 granted patents·9 pending applications·14 citations·filing 2009–2022
82Inventor score
Files withBLUEPRINT MEDICINES CORP15BERNARD-PIERROT ISABELLE1BLUEPRINT MEDICNES CORP1STRANSKY NICOLAS1VALLOT CELINE1
Top patents by PatentIndex Score
19 records- 0194US10378063B2RAF1 fusionsBLUEPRINT MEDICINES CORP·Filed 2015·Granted Aug 13, 2019·8 cites·6 claims
- 0279US10407509B2NTRK2 fusionsBLUEPRINT MEDICINES CORP·Filed 2014·Granted Sep 10, 2019·3 cites·8 claims
- 0374US2022213553A1Prkc fusionsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 0473US2022205045A1Raf1 fusionsBLUEPRINT MEDICINES CORP·Filed 2021·Application pending·0 cites
- 0572US11261497B2PRKC fusionsBLUEPRINT MEDICINES CORP·Filed 2019·Granted Mar 1, 2022·0 cites·7 claims
- 0668US2020172981A1Raf1 fusionsBLUEPRINT MEDICINES CORP·Filed 2019·Application pending·0 cites
- 0765US10669590B2PIK3CA fusionsBLUEPRINT MEDICINES CORP·Filed 2019·Granted Jun 2, 2020·0 cites·6 claims
- 0863US9233144B2Tyrosine kinase receptor TYRO3 as a therapeutic target in the treatment of cancerBERNARD-PIERROT ISABELLE·Filed 2009·Granted Jan 12, 2016·3 cites·23 claims
- 0962US10370724B2PRKC fusionsBLUEPRINT MEDICINES CORP·Filed 2015·Granted Aug 6, 2019·0 cites·7 claims
- 1060US2019389969A1Ntrk2 fusionsSTRANSKY NICOLAS·Filed 2019·Application pending·0 cites
- 1154US10875930B2PIK3C2G fusionsBLUEPRINT MEDICINES CORP·Filed 2014·Granted Dec 29, 2020·0 cites·5 claims
- 1251US10370723B2TERT fusionsBLUEPRINT MEDICINES CORP·Filed 2015·Granted Aug 6, 2019·0 cites·5 claims
- 1350US10246750B2Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusionBLUEPRINT MEDICINES CORP·Filed 2015·Granted Apr 2, 2019·0 cites·5 claims
- 1447US10370725B2FGR fusionsBLUEPRINT MEDICINES CORP·Filed 2015·Granted Aug 6, 2019·0 cites·9 claims
- 1547US2017044622A1Pik3ca fusionsBLUEPRINT MEDICINES CORP·Filed 2015·Application pending·0 cites
- 1636US2019192522A1Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitorsBLUEPRINT MEDICINES CORP·Filed 2017·Application pending·0 cites
- 1736US2017356052A1Prkacb fusionsBLUEPRINT MEDICINES CORP·Filed 2015·Application pending·0 cites
- 1834US2017044621A1Met fusionsBLUEPRINT MEDICNES CORP·Filed 2015·Application pending·0 cites
- 1933US2012282167A1Method for predicting the sensitivity of a tumor to an epigenetic treatmentVALLOT CELINE·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nicolas Stransky files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →